Arcutis officer plans 1,697-share, $45.8K stock sale

Arcutis Biotherapeutics, Inc. (ARQT) is the issuer of common stock that officer Patrick Burnett plans to sell under Rule 144.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) is the issuer of common stock that officer Patrick Burnett plans to sell under Rule 144. The notice covers a proposed sale of 1,697 shares of common stock, with an approximate aggregate market value of $45,819, and notes prior sales over the past three months.

Key Figures

Shares proposed for sale: 1,697 shares Aggregate market value of proposed sale: $45,819 Shares outstanding: 125,691,961 shares +3 more

6 metrics

Shares proposed for sale 1,697 shares Common stock covered by the Rule 144 notice

Aggregate market value of proposed sale $45,819 Approximate aggregate market value of 1,697 shares

Shares outstanding 125,691,961 shares Common shares outstanding referenced in the notice

Sale on 08/03/2026 955 shares for $24,941.54 Common stock sold during the past three months

Sale on 08/11/2026 8,300 shares for $220,129.66 Common stock sold during the past three months

Sale on 08/12/2026 6,700 shares for $174,767.62 Common stock sold during the past three months

Key Terms

Rule 144, Restricted Stock Vest, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vest financial

"Common | 08/18/2026 | Restricted Stock Vest | Arcutis Biotherapeutics"

A restricted stock vest is the moment when shares granted to an employee or executive under conditions (like staying at the company or hitting targets) officially become theirs to keep or sell. Think of it as a timed gift that unlocks only after certain rules are met. Investors watch vesting because it can change who controls shares, create potential selling pressure when large blocks unlock, and reveal how management’s incentives are aligned with company performance.

aggregate market value financial

"Common | Merrill Lynch ... | 1697 | 45819 | 125691961"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 by Patrick Burnett involve for ARQT?

The Form 144 notice covers a proposed sale of 1,697 shares of Arcutis Biotherapeutics common stock by officer Patrick Burnett. It also lists earlier sales in the prior three months, as required under Rule 144 aggregation rules.

How many ARQT shares does Patrick Burnett plan to sell under this notice?

Patrick Burnett plans to sell 1,697 shares of Arcutis Biotherapeutics common stock. The notice associates these shares with a Restricted Stock Vest dated August 18, 2026, and provides related market value information.

What is the approximate market value of the ARQT shares in this planned sale?

The proposed sale of 1,697 ARQT shares has an approximate aggregate market value of $45,819. This value reflects the market-based estimate used in the Rule 144 notice for the planned disposition.

What ARQT share sales has Patrick Burnett made in the last three months?

In the prior three months, Patrick Burnett reported three ARQT common stock sales: 955 shares for $24,941.54, 8,300 shares for $220,129.66, and 6,700 shares for $174,767.62, all disclosed as required by Rule 144.

On which market is Arcutis Biotherapeutics (ARQT) common stock listed?

Arcutis Biotherapeutics common stock is listed on NASDAQ. The Rule 144 notice identifies NASDAQ as the trading market for the common shares covered by the proposed sale and prior transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 04:27 PM Accepted by SEC EDGAR 08/19/2026 - 04:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741987
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Patrick Burnett
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	1697	45819	125691961	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2026	Restricted Stock Vest	Arcutis Biotherapeutics			1697	08/18/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	08/03/2026	955	24941.54
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	08/11/2026	8300	220129.66
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	08/12/2026	6700	174767.62

144: Remarks and Signature

Remarks
Date of Notice	08/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Patrick Burnett
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)